Cover Image

EORTC SPECTA-AYA: a unique molecular profiling platform for adolescents and young adults with cancer in Europe

For most adolescent and young adult (AYA) cancers, age-specific molecular features are poorly understood. EORTC-SPECTA, an academic translational research infrastructure for biomaterial collection, will explicitly recruit AYA patients and will therefore collect empirical data to bridge the molecular...

Full description

Saved in:
Bibliographic Details
Main Authors: Rojas, Teresa de (Author) , Kasper, Bernd (Author) , Graaf, Wilhelmina Tita Alide van der (Author) , Pfister, Stefan (Author) , Bielle, Franck (Author) , Ribalta, Teresa (Author) , Shenjere, Patrick (Author) , Preusser, Matthias (Author) , Fröhling, Stefan (Author) , Golfinopoulos, Vassilis (Author) , Morfouace, Marie (Author) , McCabe, Martin G. (Author)
Format: Article (Journal)
Language:English
Published: 29 August 2019
In: International journal of cancer
Year: 2020, Volume: 147, Issue: 4, Pages: 1180-1184
ISSN:1097-0215
DOI:10.1002/ijc.32651
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1002/ijc.32651
Verlag, lizenzpflichtig, Volltext: https://onlinelibrary.wiley.com/doi/abs/10.1002/ijc.32651
Get full text
Author Notes:Teresa de Rojas, Bernd Kasper, Winette Van der Graaf, Stefan M. Pfister, Franck Bielle, Teresa Ribalta, Patrick Shenjere, Matthias Preusser, Stefan Fröhling, Vassilis Golfinopoulos, Marie Morfouace, Martin G. McCabe
Description
Summary:For most adolescent and young adult (AYA) cancers, age-specific molecular features are poorly understood. EORTC-SPECTA, an academic translational research infrastructure for biomaterial collection, will explicitly recruit AYA patients and will therefore collect empirical data to bridge the molecular gap between pediatric and adult oncology. The initial pilot study, activated in February 2019 across Europe, will recruit 100 AYA patients (aged 12-29 years) with newly diagnosed or relapsed high-grade gliomas and high-grade bone and soft tissue sarcomas. The primary objective of the pilot is to determine feasibility and recruitment rates. Formalin-fixed tumor tissue and whole blood from study participants will be prospectively collected with clinical data and stored centrally at the Integrated BioBank of Luxembourg. Whole exome sequencing of matched tumor and blood, and tumor RNA sequencing and DNA methylation profiling will be performed at the German Cancer Research Center, Heidelberg, Germany. Virtual central pathology review of scanned diagnostic slides will be undertaken by an international expert panel, and diagnostic material returned to the participating centers. A multidisciplinary molecular tumor board will release a clinically validated report to referring clinicians within 4-6 weeks after biopsy. SPECTA-AYA constitutes a major opportunity to gain knowledge about the tumor biology of this unique age group. It incorporates notable innovative aspects: AYA specificity, pan-European academic collaboration, centralized biobanking, comprehensive molecular profiling and virtual central pathology review, among others. SPECTA-AYA will help untangle the tumor particularities of AYAs with cancer and aims to improve their access to novel drugs and personalized medicine.
Item Description:Gesehen am 16.04.2020
Physical Description:Online Resource
ISSN:1097-0215
DOI:10.1002/ijc.32651

Similar Items